| Targeting mitochondrial metabolism for precision medicine in cancer L Sainero-Alcolado, J Liaño-Pons, MV Ruiz-Pérez, ... Cell Death & Differentiation 29 (7), 1304-1317, 2022 | 187 | 2022 |
| MXD1 localizes in the nucleolus, binds UBF and impairs rRNA synthesis M del Carmen Lafita-Navarro, R Blanco, J Mata-Garrido, J Liaño-Pons, ... Oncotarget 7 (43), 69536, 2016 | 29 | 2016 |
| The MNT transcription factor autoregulates its expression and supports proliferation in MYC-associated factor X (MAX)-deficient cells MC Lafita-Navarro, J Liaño-Pons, A Quintanilla, I Varela, R Blanco, ... Journal of Biological Chemistry 295 (7), 2001-2017, 2020 | 16 | 2020 |
| The multiple faces of MNT and its role as a MYC modulator J Liaño-Pons, M Arsenian-Henriksson, J León Cancers 13 (18), 4682, 2021 | 14 | 2021 |
| Expression and activation of nuclear hormone receptors result in neuronal differentiation and favorable prognosis in neuroblastoma L Sainero-Alcolado, M Mushtaq, J Liaño-Pons, A Rodriguez-Garcia, ... Journal of Experimental & Clinical Cancer Research 41 (1), 226, 2022 | 11 | 2022 |
| A druggable conformational switch in the c-MYC transactivation domain D Lama, T Vosselman, C Sahin, J Liaño-Pons, CP Cerrato, L Nilsson, ... Nature Communications 15 (1), 1865, 2024 | 7 | 2024 |
| Target Genes of c-MYC and MYCN with Prognostic Power in Neuroblastoma Exhibit Different Expressions during Sympathoadrenal Development Y Yuan, M Alzrigat, A Rodriguez-Garcia, X Wang, TS Bexelius, JI Johnsen, ... Cancers 15 (18), 4599, 2023 | 3 | 2023 |
| Defining neuroblastoma: From origin to precision medicine L Sainero-Alcolado, T Sjöberg Bexelius, G Santopolo, Y Yuan, ... Neuro-Oncology 26 (12), 2174-2192, 2024 | 2 | 2024 |
| A novel role of MNT as a negative regulator of REL and the NF-κB pathway J Liaño-Pons, MC Lafita-Navarro, L García-Gaipo, C Colomer, ... Oncogenesis 10 (1), 5, 2021 | 2 | 2021 |
| Precision mitochondrial medicine: Uncovering pathways across diverse diseases L Sainero-Alcolado, E Garde-Lapido, J Liaño-Pons, ... Implementation of Personalized Precision Medicine, 115-169, 2025 | | 2025 |
| EZH2 inhibition sensitizes retinoic acid-driven senescence in synovial sarcoma M Mushtaq, J Liaño-Pons, J Wang, M Alzrigat, Y Yuan, MV Ruiz-Pérez, ... Cell Death & Disease 15 (11), 836, 2024 | | 2024 |
| Erratum to: Defining neuroblastoma: from origin to precision medicine L Sainero-Alcolado, TS Bexelius, G Santopolo, Y Yuan, J Liano-Pons, ... NEURO-ONCOLOGY 26 (12), 2398-2398, 2024 | | 2024 |
| Target Genes of c-MYC and MYCN with Prognostic Power in Neuroblastoma Exhibit Different Expressions during Sympathoadrenal Development. Cancers 2023, 15, 4599 Y Yuan, M Alzrigat, A Rodriguez-Garcia, X Wang, TS Bexelius, JI Johnsen, ... | | 2023 |
| The MNT transcription factor autoregulates its expression and supports proliferation in MYC-associated factor X (MAX)-deficient cells M Carmen Lafita-Navarro, J Liaño Pons, A Quintanilla, I Varela, R Blanco, ... Journal of Biological Chemistry, 295, 2020 | | 2020 |
| Nuevas interacciones de la proteína MNT y su efecto en regulación transcripcional J Liaño Pons | | 2019 |
| PO-346 The MYC antagonist MNT beyond MAX interaction MC Lafita-Navarro, J Liano-Pons, I Varela, R Blanco, J Aresti, P Carroll, ... ESMO Open 3, A157, 2018 | | 2018 |
| Study of the novel interaction between MNT and c-REL and its impact on cell proliferation and viability J Liaño Pons | | 2015 |
